S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY

Documenti analoghi

• S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
  di: Roch Houot, et al.
  Pubblicazione: (2023-08-01)
• Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma
  di: Emilie Charton, et al.
  Pubblicazione: (2026-03-01)
• S238: CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY
  di: Romain Loyaux, et al.
  Pubblicazione: (2023-08-01)
• P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
  di: Clementine Sarkozy, et al.
  Pubblicazione: (2023-08-01)
• S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
  di: Amira Marouf, et al.
  Pubblicazione: (2023-08-01)